



G Attard

Kontakt

G Attard

Publikationen (16)

STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: *Ann Oncol* 2019; 30: 1992-2003. *Ann Oncol* 2020; 31:442.

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2019; 30:e3.

James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol* 2019

STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. *Ann Oncol* 2018; 29:1235-1248.

Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol* 2017; 28:1692-1694.

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2016

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2015; 26:1589-604.

Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. *Clin Radiol* 2014

Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. *Br J Cancer* 2014

Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. *Ann Oncol* 2014; 25:657-62.

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. *Br J Cancer* 2013; 110:267-8.

Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:2579-86.

Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Lorente D, de Bono J. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. *Eur J Cancer* 2013; 50:78-84.

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:1079-84.

Pezaro C, de Bono J, Olmos D, Reid A, Seed G, Bianchini D, Omlin A, Cassidy A, Tunariu N, Mukherji D, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:325-31.

Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. *Ann Oncol* 2013; 24:1416-8.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch